GSK_ Annual_Report_2021-22

Corporate Overview Message from the Chairperson 02 Message from the Managing Director 03 Our focus brands 04 Strategic Priorities Innovation 08 Performance 10 Trust 12 Statutory Reports Notice 19 Directors’ Report and Management Discussion Analysis 30 Annexures to Directors’ Report 42 Business Responsibility and Sustainability Report 75 Financial Statements Independent Auditors’ Report 105 Financial Statements 114 Form No. AOC-1 171 Form No. AOC-2 172 Biddle Sawyer Limited 173 Consolidated Financial Statements 197 Contents With our new purpose, strategy and culture, we will move #AheadTogether continuing our legacy in General Medicines, our leadership in the Vaccines self-pay market and introduce innovative offerings through our Specialty medicines – all three will help us deliver our ambition for patients and get ahead of disease together. Our business portfolios General Medicines Our General Medicines business has a broad portfolio of established medicines with commercial leadership in Anti-infectives, Pain, Dermatology and Vitamins. Vaccines Our Vaccines business currently markets 10 vaccines across age groups for infants, adolescents and adults. Specialty Our Specialty medicines in India are focused on helping patients breathe easy through innovative offerings that combine science and technology.